HTD1801 + metformin

HTD1801 + metformin is a combination therapy under clinical investigation for the treatment of type 2 diabetes mellitus (T2D) inadequately controlled with metformin monotherapy. HTD1801 is a novel ionic salt composed of berberine and ursodeoxycholic acid, designed to improve metabolic parameters by targeting multiple pathways involved in glucose and lipid metabolism as well as liver health. Berberine activates AMP-activated protein kinase (AMPK), inhibits the NLRP3 inflammasome, stimulates the insulin receptor, and induces low-density lipoprotein receptor expression. Ursodeoxycholic acid contributes by ameliorating insulin resistance, promoting insulin secretion, and exerting anti-inflammatory and antioxidative effects. The combination aims to provide additive or synergistic benefits in glycemic control and metabolic health when used alongside standard-of-care metformin[2][4][5]. Clinical studies have shown that adding HTD1801 to ongoing metformin therapy can further reduce HbA1c levels and improve lipid profiles without significant weight change or major safety concerns[5].

Other names

HTD1801 + 二甲双胍berberine ursodeoxycholate + metformin